Lyn, along with Btk, supports the abnormal growth and survival of neoplastic mast cells. Phosphorylated Lyn has been identified in these cancerous cells, along with phosphorylated Btk, Hck, and Stat5. Dasatinib, a chemotherapy drug used to treat leukemia, is a tyrosine kinase inihibitor that binds directly to Lyn in neoplastic cells. Lyn and Btk have also been shown to be involved in IgE receptor-dependent activation. Increased Lyn activity, detected by higher amounts of phospho Lyn, has been demonstrated in breast cancer cell lines. This is likely mediated through effects of upstream regulators of Lyn, rather than mutations in Lyn itself.
Predicted to work with mouse, rat and other homologues.
Detection
Anti-Rabbit IgG
Clonality
Monoclonal
Immunogen
A synthetic phospho-peptide corresponding to residues surrounding Tyr507 of human phospho Lyn
Formulation
1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA
Isotype
Rabbit IgGk
Preparation
Protein A+G
Recommended Usage
1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
Storage
-20ºC
Pseudonyms
Tyrosine-protein kinase Lyn, Lck/Yes-related novel protein tyrosine kinase, V-yes-1 Yamaguchi sarcoma viral related oncogene homolog, p53Lyn, p56Lyn, JTK8
Gleixner KV, Mayerhofer M, Cerny-Reiterer S et al. (2011) Blood. 28: 1077-1086. Choi Y, Bocanegra M, Kwon MJ et al. (2010) Molecular and Cellular Pathology. 70: 2296-2306.